A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome


Neuren Pharmaceuticals

Status and phase

Phase 2


Fragile X Syndrome


Drug: NNZ-2566
Drug: Placebo

Study type


Funder types




Details and patient eligibility


The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.

Full description

Fragile X Syndrome is a genetically determined neurological disorder in which affected individuals are intellectually handicapped to varying degrees and display a variety of associated psychiatric symptoms. Clinically, Fragile X Syndrome is characterized by intellectual handicap, hyperactivity and attentional problems, autism spectrum symptoms, emotional lability and epilepsy. The epilepsy seen in Fragile X Syndrome is most commonly present in childhood, but then gradually remits towards adulthood. Physical features such as prominent ears and jaw, and hyper-extensibility of joints are frequently present but are not diagnostic. Intellectual handicap is the most common feature defining the phenotype. Treatment for the disorder is symptomatic - focusing on the management of symptoms - and supportive, requiring a multidisciplinary approach. This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult males with Fragile X Syndrome. The study also will also investigate measures of efficacy during treatment.


72 patients




12 to 45 years old


No Healthy Volunteers

Inclusion criteria

Fragile X Syndrome with a molecular genetic confirmation of the full FMR1 mutation.

  • Results from previously completed testing are acceptable with written documentation of the genetic results.
  • Results from PCR or Southern blot tests are acceptable
  • Results from cytogenetic testing are not acceptable but subject may be eligible if molecular genetic testing is redone.

A full mutation with mosaicism is allowed if:

  • Subject manifests full phenotypic profile of Fragile X syndrome
  • CGG Repeats >200 are detected
  • Southern blot prevails over PCR, if Southern blot shows >200 repeats and PCR results show <200 repeats.

The following results would not meet criteria:

  • Deletions
  • Point mutations
  • Mosaicism without detection of >200 CGG repeats or absence of full phenotypic profile in an individual with mosaicism
  • Males, aged 12-45 years
  • Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening
  • Subjects with a total score of 30 or greater on the Aberrant Behavior Checklist (ABC) at Screening.
  • Current treatment with no more than 3 psychotropic medications. This includes medications used to treat problems with sleep onset and sleep continuity. Melatonin for difficulties with sleep onset is permissible and is excepted from the count of psychotropic medications. Similarly, anti-epileptic medications are permitted and are not denoted as "psychotropic medications" if they are used for treatment of seizures. Use of anti-epileptics for other indications such as the treatment of mood disorders counts towards the limit of permitted medications. Concurrent use of omega-3 fatty acids is also permissible and does not count towards the allowed number of concomitant psychotropic medications. A complete list of permitted concomitant psychotropic medications can be found in Appendix A.

Concomitant medications for chronic medical conditions are permissible. Examples of chronic medical conditions include gastroesophageal reflux disease (GERD) and asthma. Every effort should be made to keep the doses and dosing regimens of these medications stable in the 4 weeks preceding Screening and during the period between Screening and the commencement of study medication.

  • Permitted psychotropic concomitant medications (except for anti-epileptic medications-see below) must be stable, in terms of dose and dosing regimen, for at least 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication.
  • Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication

Behavioral treatments excluding psychotherapy (see exclusion criteria) must be stable for 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication

a. For each enrollee, every effort should be made to maintain stable regimens of allowed concomitant medications and allowed behavioral therapies from the time of commencement of single-blind study medication until the last study assessment.

  • Sufficient expressive language capabilities to complete the Expressive Language Sampling Task.
  • Individuals with a history of seizures should have a stable pattern of seizure activity in the 3 months preceding Screening.

Exclusion criteria

  • Treatment within the two weeks prior to Screening with monoamine (MAO) inhibitors, lithium, minocycline, acamprosate, racemic baclofen, investigational metabotropic glutamate receptor subtype 5 (mGluR5) medications, d-cycloserine, oxytocin, carbetocin, tricyclic antidepressants and bupropion.
  • Patients planning to commence psychotherapy, including cognitive behavior therapy (CBT), during the period of the study or those who had begun psychotherapy, including CBT, within 6 weeks prior to Screening.
  • History of, or current, cardiovascular, renal, hepatic, respiratory and/or gastrointestinal disease, which may interfere with the absorption, distribution, metabolism or excretion of the study medication, or which may interfere with the interpretation of the safety/tolerability or efficacy of the study medication.
  • History of, or current cerebrovascular disease or clinically significant brain trauma.
  • History of, or current clinically significant endocrine disorder, e.g. hypo or hyperthyroidism, or diabetes.
  • History of, or current malignancy.
  • Current major depressive disorder (patients have to be free of the most recent episode for 3 months prior to enrollment).
  • History of a DSM-5-defined substance use disorder in the 3 months prior to Screening.
  • Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at Screening.

QT/QTcF Exclusions (any of the following):

  • QTcF > 450 msec. Three ECGs should be obtained at the time of Screening, 5 minutes apart from each other, and the results should be averaged.
  • History of risk factors for torsade de pointes (e.g. heart failure, clinically significant hypokalemia or hypomagnesemia, or a family of long QT syndrome).
  • A serum potassium at screening <3.0 mmol/L.
  • QT/QTcF prolongation previously or currently controlled with medication, in which normal QT/QTcF intervals could or can only be achieved with medication
  • Current treatment with other medications that have demonstrated QT/QTc prolongation and have this risk described in the Warnings and Precautions section of their Prescribing Information
  • Patients with significant hearing and/or visual impairments that may affect their ability to complete the test procedures.
  • Current treatment with insulin
  • Hgb A1C values outside of the normal reference range at Screening
  • Current or past treatment with insulin like growth factor IGF-1
  • Current or past treatment with growth hormone
  • Enrollment in another clinical trial within the 30 days preceding Screening
  • Previously randomized in this clinical trial
  • Allergy to strawberry

Trial design

Primary purpose




Interventional model

Parallel Assignment


Quadruple Blind

72 participants in 2 patient groups, including a placebo group

Experimental group
Glycyl-L-2-Methylpropyl-L-Glutamic Acid
Drug: NNZ-2566
Placebo (strawberry flavored solution)
Placebo Comparator group
Strawberry flavored solution and Water
Drug: Placebo

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems